<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Sept. 07, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6267711/therapeutic-vaccines-market-type-vaccine-method?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=knz3h3&amp;utm_campaign=2345116+-+Assessment+of+the+%2411+Billion+Therapeutic+Vaccines+Market+2026%3a+Cancer+Vaccine+Pipeline+Expands+Beyond+300+Candidates&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Therapeutic Vaccines Market by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Therapeutic Area, Route of Administration, Key Geographical Regions - Trends and Forecast Till 2035">"Therapeutic Vaccines Market by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Therapeutic Area, Route of Administration, Key Geographical Regions - Trends and Forecast Till 2035"</a> has been added to ResearchAndMarkets.com's offering. The global therapeutic vaccines market is projected to expand from USD 11 billion in 2026 to USD 86.8 billion by 2035, representing a compound annual growth rate of approximately 25.8% during the forecast period. Market expansion is being supported by the rising global burden of cancer and chronic infectious diseases, continued investment in immuno-oncology, and rapid progress in mRNA, DNA and neoantigen-based vaccine platforms. More than 300 therapeutic vaccine candidates are currently under development across multiple clinical stages, while over 400 cancer vaccine clinical trials are active worldwide. Advances in genomic sequencing, bioinformatics, adjuvant technologies and formulation stability are strengthening the clinical and commercial potential of next-generation therapeutic vaccines. Personalized mRNA Cancer Vaccines Reshape the Market Personalized neoantigen mRNA vaccines represent one of the therapeutic vaccines market's most significant growth opportunities. These candidates use tumor-specific genomic information to support highly targeted immune responses. Encouraging clinical findings from Moderna and Merck involving an investigational personalized cancer vaccine administered with Keytruda have reinforced confidence in combination immunotherapy and attracted further investment to the mRNA cancer vaccine segment. Pipeline activity remains concentrated among established innovators, with Moderna and BioNTech accounting for a substantial proportion of active development. Large pharmaceutical companies are also expanding their capabilities through acquisitions, licensing agreements and strategic collaborations rather than relying exclusively on internal platform development. Pfizer, Sanofi and Bayer are among the companies pursuing partnerships or investments involving RNA technologies and specialized developers. Market Growth Drivers and Development Challenges Demand for therapeutic vaccines is increasing as healthcare systems confront cancer, HIV, hepatitis B, hepatitis C and other persistent diseases associated with prolonged treatment, relapse and high costs. Improved screening and diagnostic capabilities may also expand the eligible patient population by enabling therapeutic intervention at earlier disease stages. Technological progress in DNA and mRNA platforms, delivery vectors, adjuvants and neoantigen selection is enabling stronger and more targeted cellular immune responses. These advances align with the pharmaceutical industry's broader shift toward precision medicine and patient-specific treatment strategies. Despite strong momentum, developers continue to face challenges related to patient and tumor heterogeneity, antigen selection, delivery systems, dosing regimens and clinical trial design. Variability in immune response can make it difficult to demonstrate consistent clinical benefits across large patient populations. High development costs, candidate attrition and late-stage clinical setbacks may also affect investment and commercialization timelines, particularly for smaller biotechnology companies. Key Therapeutic Vaccines Market Findings <ul><li>Peptide vaccines are expected to retain the largest market share, supported by their specificity, safety profile, manufacturing scalability and broad application in oncology and infectious disease programs.</li><li>DNA vaccines are projected to record a higher CAGR due to rapid design cycles, manufacturing flexibility and increasing investment in genetic medicine and precision immunotherapy.</li><li>Oncological disorders are expected to remain the leading therapeutic area, reflecting the global cancer burden and extensive investment in cancer immunotherapy.</li><li>Infectious diseases are forecast to represent a high-growth segment as developers pursue new treatments for chronic and difficult-to-treat viral and bacterial infections.</li><li>More than 10% of the global therapeutic vaccine pipeline has progressed to Phase III, indicating increasing clinical maturity and regulatory engagement.</li><li>Venture capital and seed financing continue to support emerging companies. Recent examples include Reprogram Biosciences' USD 6 million seed financing and ErVimmune's €17 million Series A funding.</li></ul> Regional Market Outlook North America is expected to maintain the largest share of the global therapeutic vaccines market in 2026. Its leadership is supported by advanced healthcare infrastructure, established biotechnology and pharmaceutical industries, substantial immunotherapy research funding, mature clinical trial networks and supportive regulatory pathways. Asia-Pacific is projected to register the fastest regional CAGR through 2035. Growth is being driven by higher healthcare expenditure, expanding biopharmaceutical research capacity, improving clinical infrastructure and government support for biotechnology innovation. China, India, Japan and South Korea are expected to contribute significantly to regional market development. Market Segmentation The therapeutic vaccines market analysis covers peptide, antigen, DNA and dendritic vaccines. It also evaluates autologous and allogeneic compositions; monotherapy and combination therapy strategies; oncological, infectious, autoimmune and other therapeutic areas; and intradermal, intramuscular, subcutaneous, intranasal, oral and additional administration routes. Geographic analysis includes North America, Europe, Asia-Pacific and the rest of the world, supported by country-level projections across key markets. Competitive Landscape Companies profiled in the therapeutic vaccines market include: <ul><li>BioNTech</li><li>GlobeImmune</li><li>Immatics</li><li>Immunitor</li><li>Inovio Pharmaceuticals</li><li>Moderna</li></ul> The report examines company portfolios, clinical pipelines, financial activity, partnerships, acquisitions, licensing agreements and recent strategic developments. Research Coverage The study provides therapeutic vaccines market sizing, ten-year revenue forecasts, pipeline assessments, company profiles, clinical trial analysis, academic grant evaluation, partnership trends and start-up benchmarking. It also includes adjacent-market assessments of preventive vaccines and vaccine contract manufacturing to provide broader context on commercialization and supply-chain opportunities. Industry findings were informed by discussions with executives, scientific leaders, oncology researchers, physician-scientists, public health specialists and translational research professionals from companies and institutions in the United States, Europe and Asia. Why This Report Matters The report enables pharmaceutical companies, biotechnology developers, investors, healthcare organizations and other stakeholders to evaluate therapeutic vaccines market opportunities, competitive positioning and emerging technology trends. It offers detailed revenue projections across major segments, identifies growth drivers and commercialization barriers, and supports evidence-based decisions concerning research, partnerships, investment and market-entry strategies. Report purchasers also receive complementary presentation and spreadsheet data packs, an in-depth walkthrough with the research team, eligible content customization and a complimentary update when the report is more than six months old. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6267711/therapeutic-vaccines-market-type-vaccine-method?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=knz3h3&amp;utm_campaign=2345116+-+Assessment+of+the+%2411+Billion+Therapeutic+Vaccines+Market+2026%3a+Cancer+Vaccine+Pipeline+Expands+Beyond+300+Candidates&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/mmt01s</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YmE0YzIyZWYtNWY3NC00YWZjLTg0OTItZDhiZDdiNWUyYjQ2LTEwMjY3MzctMjAyNi0wOS0wNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Assessment of the $11 Billion Therapeutic Vaccines Market 2026: Cancer Vaccine Pipeline Expands Beyond 300 Candidates

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn